Subhashis Banerjee
5PUBLICATIONS
23CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Mar 06, 2025
Correction to: Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials.April W Armstrong, Matthias Augustin, Jennifer L Beaumont
|Mar 06, 2025
Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials.April W Armstrong, Mark Lebwohl, Richard B Warren
|Dec 06, 2024
Deucravacitinib in Japanese patients with plaque, generalized pustular, or erythrodermic psoriasis: Patient-reported outcomes in the POETYK PSO-4 study.Yayoi Tada, April W Armstrong, Shinichi Imafuku
|Sep 16, 2024
Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial.Ian M Catlett, Lu Gao, Yanhua Hu
|Jul 30, 2024
Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials.April W Armstrong, Matthias Augustin, Jennifer L Beaumont
Pageof 1
Frequent Collaborators
4 joint publications
April W Armstrong
2 joint publications
Jennifer L Beaumont
2 joint publications
Tan P Pham
2 joint publications
Stacie Hudgens
2 joint publications
Akimichi Morita
1 joint publications
Ian M Catlett
1 joint publications
Lu Gao
1 joint publications
Yanhua Hu
1 joint publications
James G Krueger
1 joint publications
Yayoi Tada
